Financial Performance - Net revenue for the three months ended March 31, 2025, was $458.4 million, a decrease of $36.7 million, or 7.4%, compared to $495.1 million for the same period in 2024[73] - Same-unit net revenue increased by $26.1 million, or 6.2%, driven by a $19.4 million increase from net reimbursement-related factors and a $6.7 million increase related to patient service volumes[73] - Adjusted EBITDA for the three months ended March 31, 2025, was $49.2 million, compared to $37.2 million for the same period in 2024, reflecting an increase of $11.9 million[72] - Adjusted EPS for the three months ended March 31, 2025, was $0.33, compared to $0.20 for the same period in 2024, representing a 65% increase[72] - Income from operations increased by $16.2 million, or 102.0%, to $32.1 million for the three months ended March 31, 2025, compared to $15.9 million for the same period in 2024[79] - Operating margin improved to 8.4% for the three months ended March 31, 2025, up from 4.9% for the same period in 2024[80] - Net income rose to $20.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024[83] - Adjusted EBITDA increased to $49.2 million for the three months ended March 31, 2025, from $37.2 million for the same period in 2024[83] Expenses - Practice salaries and benefits decreased by $32.1 million, or 8.7%, to $337.0 million for the three months ended March 31, 2025, compared to $369.1 million for the same period in 2024[74] - General and administrative expenses were $58.6 million for the three months ended March 31, 2025, a decrease of $1.6 million compared to $60.2 million for the same period in 2024[76] - Transformational and restructuring related expenses were $6.6 million for the three months ended March 31, 2025, compared to $8.5 million for the same period in 2024[78] - Total non-operating expenses decreased to $4.0 million for the three months ended March 31, 2025, from $8.1 million for the same period in 2024[81] Cash Flow and Liquidity - Cash used in operating activities decreased to $116.1 million for the three months ended March 31, 2025, from $122.6 million for the same period in 2024[87] - As of March 31, 2025, the company had $99.0 million in cash and cash equivalents, down from $229.9 million at December 31, 2024[85] - The outstanding principal balance on the Amended Credit Agreement was $210.9 million as of March 31, 2025[96] - A 1% change in interest rates would impact income before taxes by approximately $2.1 million per year based on the outstanding balance of the Amended Credit Agreement[104] Operational Metrics - The percentage of patient service revenue reimbursed under government-sponsored healthcare programs decreased during the three months ended March 31, 2025, compared to the same period in 2024[61] - Days sales outstanding (DSO) improved to 47.6 days at March 31, 2025, down from 52.2 days at March 31, 2024[89] Strategic Changes - The company completed the exit of its pediatric office-based practices as of December 31, 2024, to focus on hospital-based and maternal-fetal medicine services[62] - The company anticipates potential impacts from changes in government-sponsored healthcare programs and the expiration of COVID-19 related emergency declarations[67]

• Net revenue of $458 million; • Net income of $21 million; and • Adjusted EBITDA of $49 million. Operating Results– Three Months Ended March 31, 2025 Pediatrix's net revenue for the three months ended March 31, 2025 was $458.4 million, compared to $495.1 million for the prior-year period. This decrease reflects the impact of non-same unit activity, primarily practice dispositions, partially offset by growth in same-unit net revenue of 6.2 percent. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice Pres ...

Physician services provider Pediatrix Medical Group, Inc. (MD) is set to report its first-quarter 2025 results on May 6, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 25 cents per share and $454.5 million, respectively. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year- ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Figure 1 Midland Announces the Acquisition of the Kan Gold Project Figure 2 Midland Announces the Acquisition of the Kan Gold Project Figure 3 Midland Announces the Acquisition of the Kan Gold Project Figure 4 Midland Announces the Acquisition of the Kan Gold Project Figure 5 Midland Announces the Acquisition of the Kan Gold Project Figure 6 Midland Announces the Acquisition of the Kan Gold Project Figure 7 Midland Announces the Acquisition of the Kan Gold Project Figure 8 <img ...

Figure 1 Midland Increases its Copper Land Position in the Labrador Trough Figure 2 Midland Increases its Copper Land Position in the Labrador Trough MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to report that 167 mining claims with strong copper potential were designated in the central part of the Labrador Trough, Quebec (new “Kuiper” project; Figures 1A and 1B), following the identification of several highly favourable parameters for copp ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Viewpoint - Pediatrix Medical Group (MD) shows potential for upside with a mean price target of $18.21, indicating a 28% increase from the current trading price of $14.23 [1] Price Target Analysis - The mean estimate consists of seven short-term price targets with a standard deviation of $1.35, suggesting variability in analyst predictions [2] - The lowest estimate of $17 indicates a 19.5% increase, while the highest estimate suggests a 47.6% surge to $21 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [7] Earnings Estimates - Analysts have shown increasing optimism about MD's earnings prospects, with a strong consensus in revising EPS estimates higher [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 6.1%, with five estimates moving higher and one lower [10] - MD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Analyst Behavior - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated expectations [6] - Despite the skepticism surrounding price targets, the direction implied by them can serve as a useful guide for potential price movements [12]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lose momentum if future growth does not justify high valuations [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, utilizing tools like the Zacks Momentum Style Score to identify potential opportunities [3] Group 2: Pediatrix Medical Group (MD) Analysis - Pediatrix Medical Group (MD) has shown a price increase of 1.4% over the past four weeks, indicating growing investor interest [4] - The stock has gained 4.4% over the past 12 weeks, with a beta of 1.49, suggesting it moves 49% more than the market [5] - MD has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to MD earning a Zacks Rank 1 (Strong Buy), which is associated with strong momentum effects [7] - MD is trading at a Price-to-Sales ratio of 0.61, suggesting it is undervalued as investors pay only 61 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides MD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stocks based on various investing styles [9]

Core Viewpoint - Pediatrix Medical Group, Inc. (MD) has experienced a significant stock price increase of 37.7% over the past six months, outperforming the industry and sector declines of 12.9% and 9.4%, respectively, while the S&P 500 Index rose by 4.6% during the same period [1] Group 1: Stock Performance - Currently trading at $14.64, MD remains below its 52-week high of $17.67, indicating potential for further growth [4] - The stock is trading above its 50-day and 200-day moving averages, suggesting solid upward momentum [4] Group 2: Growth Drivers - The rising share of commercial births in Florida is a crucial tailwind for the company, expected to support margin growth [5] - The company is exiting its affiliated office-based practices, focusing on core hospital-based services, which is anticipated to contribute to EBITDA improvement [5] - Management forecasts adjusted EBITDA between $215 million and $235 million for 2025, with a midpoint indicating a 0.4% improvement from the 2024 reported figure [6] Group 3: Financial Estimates - The Zacks Consensus Estimate for 2025 adjusted earnings for Pediatrix Medical is currently pegged at $1.54 per share, indicating a 2% year-over-year growth [9] - The consensus for 2024 and 2025 revenues is estimated at $1.9 billion and $1.91 billion, respectively [9] Group 4: Investment Opportunity - Despite recent stock price growth, Pediatrix Medical is trading at a discount compared to the industry average, with an attractive forward 12-month price-to-earnings ratio of 9.42, lower than the industry average of 15.72 [8] - The company has a Value Score of A, indicating a compelling investment opportunity [8] Group 5: Strategic Initiatives - Stable same-facility patient volume growth is likely to continue, supporting the company's top line [7] - Hospital contract administrative fees are on the rise, with a 4% increase projected for 2024 [7] - The company is actively pursuing inorganic growth to expand its national network of physician practices in women's and children's services, including a recent acquisition of a maternal-fetal medicine practice for $9.7 million [6]